$CRSP
CRISPR Therapeutics AG Stock $crsp

$crsp Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000156459020004355 Filed on February 12, 2020

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$77.02M	$211.9M	$318.0K
YoY Change	66870.43%	37542.63%	-70.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.30M	$15.50M	$15.80M
YoY Change	4.85%	51.96%	24.41%
% of Gross Profit
Research & Development	$48.80M	$57.20M	$39.53M
YoY Change	69.44%	43.72%	54.23%
% of Gross Profit
Depreciation & Amortization	$1.440M	$1.300M	$1.000M
YoY Change	51.58%	62.5%	11.11%
% of Gross Profit
Operating Expenses	$66.03M	$72.77M	$55.30M
YoY Change	45.63%	45.54%	44.11%
Operating Profit	$10.98M	$139.2M	-$54.98M
YoY Change	-124.28%	-381.52%	47.46%
Interest Expense	$0.00	-$3.400M	-$1.000M
YoY Change	-100.0%	240.0%	-16.67%
% of Operating Profit	0.0%	-2.44%
Other Income/Expense, Net	$19.60M	-$466.0K	$1.369M
YoY Change	-1881.82%	-59.19%	584.5%
Pretax Income	$30.50M	$138.7M	-$53.61M
YoY Change	-164.35%	-374.25%	40.04%
Income Tax	$0.00	$300.0K	$100.0K
% Of Pretax Income	0.0%	0.22%
Net Earnings	$30.54M	$138.4M	-$53.70M
YoY Change	-164.18%	-372.96%	39.91%
Net Earnings / Revenue	39.66%	65.32%	-16886.48%
Basic Earnings Per Share	$0.53	$2.52	-$1.01
Diluted Earnings Per Share	$0.51	$2.40	-$1.01
COMMON SHARES
Basic Shares Outstanding	57.40M	54.83M	53.19M
Diluted Shares Outstanding	60.23M	57.60M	53.19M

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$943.8M	$629.7M	$427.9M
YoY Change	106.7%	29.22%	33.84%
Cash & Equivalents	$943.8M	$629.7M	$427.9M
Short-Term Investments	$0.00
Other Short-Term Assets	$43.70M	$34.30M	$10.30M
YoY Change	350.52%	289.77%	4.04%
Inventory
Prepaid Expenses
Receivables	$99.00K	$39.00K	$321.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$987.5M	$664.1M	$438.5M
YoY Change	111.74%	33.7%	32.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.33M	$21.07M	$20.16M
YoY Change	69.35%	16.45%	9.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.097M	$668.0K	$669.0K
YoY Change	63.98%	2.77%	-82.85%
Total Long-Term Assets	$79.21M	$56.53M	$55.77M
YoY Change	250.14%	154.45%	146.78%
TOTAL ASSETS
Total Short-Term Assets	$987.5M	$664.1M	$438.5M
Total Long-Term Assets	$79.21M	$56.53M	$55.77M
Total Assets	$1.067B	$720.6M	$494.2M
YoY Change	118.14%	38.87%	39.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.944M	$3.374M	$7.143M
YoY Change	17.26%	-35.38%	58.73%
Accrued Expenses	$30.18M	$22.40M	$18.63M
YoY Change	44.73%	-13.31%	46.68%
Deferred Revenue	$960.0K	$47.73M
YoY Change	841.18%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$57.11M	$79.78M	$31.41M
YoY Change	105.82%	147.16%	69.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.40M	$235.0K	$220.0K
YoY Change	5823.87%	-13.92%	-99.68%
Total Long-Term Liabilities	$14.40M	$235.0K	$220.0K
YoY Change	5823.87%	-13.92%	-99.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.11M	$79.78M	$31.41M
Total Long-Term Liabilities	$14.40M	$235.0K	$220.0K
Total Liabilities	$127.3M	$128.7M	$126.6M
YoY Change	31.51%	26.7%	43.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$224.7M	-$255.3M	-$393.7M
YoY Change	-22.93%	4.62%
Common Stock	$1.164B	$847.2M	$761.4M
YoY Change	70.25%	28.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$63.00K	$57.00K	$57.00K
YoY Change	10.53%	0.0%
Treasury Stock Shares	$250.2K	$257.0K	$257.0K
Shareholders Equity	$939.4M	$591.9M	$367.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.067B	$720.6M	$494.2M
YoY Change	118.14%	38.87%	39.97%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$30.54M	$138.4M	-$53.70M
YoY Change	-164.18%	-372.96%	39.91%
Depreciation, Depletion And Amortization	$1.440M	$1.300M	$1.000M
YoY Change	51.58%	62.5%	11.11%
Cash From Operating Activities	$3.380M	$133.4M	-$36.38M
YoY Change	-111.91%	-768.1%	44.31%
INVESTING ACTIVITIES
Capital Expenditures	-$950.0K	-$2.460M	-$2.170M
YoY Change	-5.0%	256.52%	317.31%
Acquisitions
YoY Change
Other Investing Activities	$8.010M
YoY Change
Cash From Investing Activities	$7.060M	-$2.460M	-$2.170M
YoY Change	-806.0%	256.52%	317.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	304.7M	70.89M	29.65M
YoY Change	-24092.91%	-62.34%	694.91%
NET CHANGE
Cash From Operating Activities	3.380M	133.4M	-36.38M
Cash From Investing Activities	7.060M	-2.460M	-2.170M
Cash From Financing Activities	304.7M	70.89M	29.65M
Net Change In Cash	315.2M	201.9M	-8.900M
YoY Change	-1128.56%	20.46%	-59.55%
FREE CASH FLOW
Cash From Operating Activities	$3.380M	$133.4M	-$36.38M
Capital Expenditures	-$950.0K	-$2.460M	-$2.170M
Free Cash Flow	$4.330M	$135.9M	-$34.21M
YoY Change	-115.82%	-804.77%	38.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	Baarerstrasse 14
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943771000
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	88000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88000
CY2019Q4	crsp	Prepaid Expense And Other Assets Related Parties Current PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent	0
CY2018Q4	crsp	Prepaid Expense And Other Assets Related Parties Current PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent	3417000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9658000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	466395000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18500000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	289000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3163000
CY2019Q4	crsp	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	0
CY2018Q4	crsp	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	1700000
CY2019Q4	crsp	Contract With Customer Liability Current With Related Parties ContractWithCustomerLiabilityCurrentWithRelatedParties	0
CY2018Q4	crsp	Contract With Customer Liability Current With Related Parties ContractWithCustomerLiabilityCurrentWithRelatedParties	102000
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1202000
CY2019Q4	crsp	Contract With Customer Liability Noncurrent With Related Parties ContractWithCustomerLiabilityNoncurrentWithRelatedParties	0
CY2018Q4	crsp	Contract With Customer Liability Noncurrent With Related Parties ContractWithCustomerLiabilityNoncurrentWithRelatedParties	57780000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11052000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44050000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103901006
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90343803
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61034025
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52160798
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60783799
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51852862
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	250226
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	307936
CY2018	us-gaap	Revenues Revenues	3124000
CY2017	us-gaap	Revenues Revenues	40997000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69800000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5467000
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4275000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	669000
CY2019Q4	us-gaap	Assets Assets	1066752000
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001674416
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	99000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43677000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	987547000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31330000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	235000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5041000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41502000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1097000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14395000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000
CY2018Q4	us-gaap	Assets Assets	489016000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	489016000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5944000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	392195000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1066752000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5069000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8489000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	960000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	583000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	243000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10950000
CY2019Q4	us-gaap	Liabilities Liabilities	127327000
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	119000
CY2018Q4	us-gaap	Liabilities Liabilities	96821000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1847000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1584000
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	63000
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	57000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1162345000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	682245000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224711000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-291569000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	179362000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30180000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	102000
CY2018Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	402000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20852000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57106000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27746000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11776000
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	57780000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63488000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164428000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66608000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1749000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-68357000
CY2019	us-gaap	Operating Expenses OperatingExpenses	242850000
CY2018	us-gaap	Operating Expenses OperatingExpenses	162067000
CY2017	us-gaap	Operating Expenses OperatingExpenses	105645000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-158943000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-64648000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5485000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48294000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	46740000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1960000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	67306000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	553000
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	939425000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000
CY2019	dei	Security12b Title Security12bTitle	Common Shares, nominal value CHF 0.03 par value
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16001000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	66873000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165003000
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68317000
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-37923
CY2019	dei	Entity Registrant Name EntityRegistrantName	CRISPR THERAPEUTICS AG
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6300
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Zug
CY2019	dei	Entity Address Country EntityAddressCountry	CH
CY2019	dei	City Area Code CityAreaCode	41 (0)41
CY2019	dei	Local Phone Number LocalPhoneNumber	561 32 77
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	2500000000
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60845708
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	456649000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	430983000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	315934000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15000
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20718000
CY2019	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	-663000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	24983000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	249000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20600000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20566000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	448000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40000
CY2019	us-gaap	Revenues Revenues	289590000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113773000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35845000
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1763000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	318670000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49524000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	15000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	242912000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	456649000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239758000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5041000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3163000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	948812000
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2017	us-gaap	Profit Loss ProfitLoss	-68357000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4725000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3519000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26033000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3024000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	44057000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	34985000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	18873000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2538000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-531000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5467000
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4275000
CY2019	us-gaap	Profit Loss ProfitLoss	66858000
CY2018	us-gaap	Profit Loss ProfitLoss	-164981000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1210000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-197000
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54392304
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47964368
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40057365
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.17
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56932798
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47964368
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40057365
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	746000
CY2018	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3124000
CY2017	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	4760000
CY2019	crsp	Research And Development Expense From Related Party ResearchAndDevelopmentExpenseFromRelatedParty	14459000
CY2018	crsp	Research And Development Expense From Related Party ResearchAndDevelopmentExpenseFromRelatedParty	23982000
CY2017	crsp	Research And Development Expense From Related Party ResearchAndDevelopmentExpenseFromRelatedParty	4523000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	232846000
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	59000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2608000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20636000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	40000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-68357000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	187832000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	307053000
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	113000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8563000
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	57000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39260000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	392195000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414789000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	43000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	939425000
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1763000
CY2018	crsp	Non Cash Expense Related To Collaboration Agreement NonCashExpenseRelatedToCollaborationAgreement	15582000
CY2019	crsp	Gain Loss From Consolidation Of Subsidiary GainLossFromConsolidationOfSubsidiary	16000000
CY2018	us-gaap	Other Noncash Income OtherNoncashIncome	169000
CY2017	us-gaap	Other Noncash Income OtherNoncashIncome	9000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	32618000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3342000
CY2018	crsp	Stock Options Issuance Costs StockOptionsIssuanceCosts	375000
CY2017	crsp	Costs For Proposed Supplemental Offering In Accounts Payable And Accrued Expenses CostsForProposedSupplementalOfferingInAccountsPayableAndAccruedExpenses	290000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943771000
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3154000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	242912000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4117000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1811000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	334000
CY2019	crsp	Stock Options Issuance Costs StockOptionsIssuanceCosts	295000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5025000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12110000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-831000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-45146000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-296000
CY2018	crsp	Increase Decrease In Deferred Rent Payable IncreaseDecreaseInDeferredRentPayable	-709000
CY2017	crsp	Increase Decrease In Deferred Rent Payable IncreaseDecreaseInDeferredRentPayable	-522000
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	270000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56677000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96239000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70093000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6684000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2773000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7814000
CY2019	crsp	Net Cash And Restricted Cash Received In Connection With Acquisition Of Controlling Interest NetCashAndRestrictedCashReceivedInConnectionWithAcquisitionOfControllingInterest	8009000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1325000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2773000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8314000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	415019000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	307053000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15964000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8938000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2608000
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	57000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2608000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-22000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	489000000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	216900000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-75758000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	242912000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	948812000
CY2018	us-gaap	Depreciation Depreciation	3500000
CY2017	us-gaap	Depreciation Depreciation	3000000.0
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-10-31
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224700000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943800000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66900000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943800000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	456600000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5000000.0
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3200000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31330000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-balance Sheet Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss. </p>
CY2019Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2018Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1202000
CY2018	us-gaap	Sublease Income SubleaseIncome	176000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43376000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25875000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12046000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7375000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18500000
CY2019	us-gaap	Depreciation Depreciation	4700000
CY2019	crsp	Cost Sharing Expenses Accrued CostSharingExpensesAccrued	1500000
CY2018	crsp	Cost Sharing Expenses Accrued CostSharingExpensesAccrued	1900000
CY2019	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	2900000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15229000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7321000
CY2019Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9434000
CY2018Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	7973000
CY2019Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	750000
CY2018Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	625000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2040000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1848000
CY2019Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	2311000
CY2018Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	2193000
CY2019Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	407000
CY2018Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	294000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	598000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30180000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20852000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41502000
CY2019Q4	crsp	Lease Assets LeaseAssets	41502000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8489000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44050000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52539000
CY2019	crsp	Joint Venture Agreement Date JointVentureAgreementDate	2015-12-19
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	8067000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4554000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	4282000
CY2019	us-gaap	Sublease Income SubleaseIncome	525000
CY2019	us-gaap	Lease Cost LeaseCost	16378000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13963000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11824000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10167000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10269000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8308000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	15678000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	70209000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17670000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52539000
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.099
CY2019	crsp	Operating Lease Cash Payments Included In Measurement Of Lease Liabilities OperatingLeaseCashPaymentsIncludedInMeasurementOfLeaseLiabilities	8420000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8420000
CY2018	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	2400000
CY2017	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	1200000
CY2019Q4	crsp	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	1226000
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6784000
CY2019Q4	crsp	Prepaid Expenses And Other Current Assets Fair Value Disclosure PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure	2565000
CY2019Q4	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	9340000
CY2019Q4	crsp	Operating Lease Assets Fair Value Disclosure OperatingLeaseAssetsFairValueDisclosure	11003000
CY2019Q4	crsp	Accrued Expenses And Other Current Liabilities Fair Value Disclosure AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure	3915000
CY2019Q4	crsp	Operating Lease Liabilities Fair Value Disclosure OperatingLeaseLiabilitiesFairValueDisclosure	11003000
CY2019Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	16000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103900000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90300000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2019Q4	crsp	Common Stock Registered Share Capital CommonStockRegisteredShareCapital	61037000
CY2018Q4	crsp	Common Stock Registered Share Capital CommonStockRegisteredShareCapital	52268000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103901000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90344000
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1230729
CY2019	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote for each Common Share
CY2019	us-gaap	Dividends Dividends	0
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49500000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39300000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49524000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39260000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20636000
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	96200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2832784
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2209597
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2999847
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3322000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.16
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	51.73
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47964368
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40057365
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.98
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.57
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.82
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.16
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.689
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.719
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.725
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6689311
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.42
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	68572000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2832784
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.16
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1180644
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.91
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	559014
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	35.35
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7782437
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	231554000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3328398
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.07
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	122774000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7782437
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	31.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	231554000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	42200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38300000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12300000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-68357000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	66858000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-164981000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68357000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54392304
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5966000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5184000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	9155000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-68357000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	66858000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-164981000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-68357000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54392304
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47964368
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40057365
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56932798
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47964368
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40057365
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.17
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3897754
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7016653
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6419854
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	58151000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-170394000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3834000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3785000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	49000
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-48408000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-53699000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2018Q3	us-gaap	Revenues Revenues	563000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	49995000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-37286000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-49432000
CY2018Q2	us-gaap	Revenues Revenues	1088000
CY2018Q4	us-gaap	Revenues Revenues	115000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	38374000
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	45343000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26997000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-45228000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-71792000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	67306000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-164428000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-66608000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	423000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	416000
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1533000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	59000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	131000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	42000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-6000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	482000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	547000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1569000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-34000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	477000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-297000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-34000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	180000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	448000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	553000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1749000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.093
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.093
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.093
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.021
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.025
CY2019	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.001
CY2018	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.010
CY2017	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.014
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.029
CY2019	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	-0.122
CY2018	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0.000
CY2017	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.052
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.018
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.109
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.141
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.094
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.026
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	178000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	882000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	29000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	13000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5231000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31496000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	354000
CY2019Q1	us-gaap	Revenues Revenues	328000
CY2019Q2	us-gaap	Revenues Revenues	318000
CY2019Q3	us-gaap	Revenues Revenues	211928000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25418000
CY2019Q4	us-gaap	Revenues Revenues	77016000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	48751000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	163000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2754000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1212000
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2868000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1816000
CY2019Q4	crsp	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	14214000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3300000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	51000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5217000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2871000
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	20000
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3264000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7150000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60953000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40042000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45913000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36208000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15040000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3901000
CY2019Q4	crsp	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	11068000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	40000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	20000
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	22000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15029000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3856000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11000
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	22000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	526100000
CY2019	crsp	Operating Loss Carryforwards Expiration Period OperatingLossCarryforwardsExpirationPeriod	2022
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5200000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4800000
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2018Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2017Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	354000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	55301000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	72765000
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	66033000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48423000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-47590000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-54983000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	139163000
CY2018Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51688383
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	10983000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	138423000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	30542000
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.52
CY2018Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51688383
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.53
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.40
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52093208
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53188041
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54829057
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57395839
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52093208
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53188041
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57598901
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60233927
CY2018Q1	us-gaap	Revenues Revenues	1358000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	28355000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-28300000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-38380000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-50711000
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.07
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45877428
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46842316
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47391988
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45877428
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46842316
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47391988

Files In Submission

Name	View Source	Status
0001564590-20-004355-index-headers.html	Edgar Link	pending
0001564590-20-004355-index.html	Edgar Link	pending
0001564590-20-004355.txt	Edgar Link	pending
0001564590-20-004355-xbrl.zip	Edgar Link	pending
crsp-10k_20191231.htm	Edgar Link	pending
crsp-10k_20191231_htm.xml	Edgar Link	completed
crsp-20191231.xsd	Edgar Link	pending
crsp-20191231_cal.xml	Edgar Link	unprocessable
crsp-20191231_def.xml	Edgar Link	unprocessable
crsp-20191231_lab.xml	Edgar Link	unprocessable
crsp-20191231_pre.xml	Edgar Link	unprocessable
crsp-ex1025_256.htm	Edgar Link	pending
crsp-ex1028_255.htm	Edgar Link	pending
crsp-ex1029_517.htm	Edgar Link	pending
crsp-ex1030_515.htm	Edgar Link	pending
crsp-ex1031_516.htm	Edgar Link	pending
crsp-ex1032_254.htm	Edgar Link	pending
crsp-ex211_9.htm	Edgar Link	pending
crsp-ex231_6.htm	Edgar Link	pending
crsp-ex311_10.htm	Edgar Link	pending
crsp-ex312_7.htm	Edgar Link	pending
crsp-ex31_84.htm	Edgar Link	pending
crsp-ex321_11.htm	Edgar Link	pending
crsp-ex41_117.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmlwlfosr3yk000001.jpg	Edgar Link	pending
gv5ivofwdv4c000001.jpg	Edgar Link	pending
gv5ivofwdv4c000002.jpg	Edgar Link	pending
gv5ivofwdv4c000003.jpg	Edgar Link	pending
gv5ivofwdv4c000004.jpg	Edgar Link	pending
gv5ivofwdv4c000005.jpg	Edgar Link	pending
gv5ivofwdv4c000006.jpg	Edgar Link	pending
gv5ivofwdv4c000007.jpg	Edgar Link	pending
gv5ivofwdv4c000008.jpg	Edgar Link	pending
gv5ivofwdv4c000009.jpg	Edgar Link	pending
gv5ivofwdv4c000010.jpg	Edgar Link	pending
gv5ivofwdv4c000011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRSP
CRISPR Therapeutics AG Stock $crsp

2019 Q4 Form 10-K Financial Statement

#000156459020004355 Filed on February 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP CRISPR Therapeutics AG Stock $crsp

2019 Q4 Form 10-K Financial Statement

#000156459020004355 Filed on February 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP
CRISPR Therapeutics AG Stock $crsp